Table 1 Survey responses for MSI testing for all respondents
Testing on biopsy? | Testing on resection? | Testing on extra-colonic GI? | Method of assessment? | Subsequent testing? | Subsequent testing for wild-type BRAF | Incorporate into histologic grade? | Type of Institution? | |
|---|---|---|---|---|---|---|---|---|
Responses | ||||||||
A | 58% | 79% | 9% | 2% | 63% | 54% | 24% | 61% |
B | 6% | 7% | 2% | 76% | 12% | 24% | 76% | 30% |
C | 2% | 0% | 19% | 3% | 7% | 18% | NA | 3% |
D | 24% | 4% | 54% | 18% | 3% | 4% | NA | 5% |
E | 9% | 9% | 16% | 1% | 15% | NA | NA | NA |
No response | 0% | 0% | 0% | 0% | 2% | NA | 0% | 0% |
Answer key | ||||||||
A | Universal | Universal | Universal | DNA-PCR for MSI | BRAF mutation | MLH1 promoter | Yes | Academic |
B | <70 or >70 and fulfill Bethesda Criteria | <70 or >70 and fulfill Bethesda Criteria | All intestinal adenocarcinoma | IHC for 4 MMR proteins | MLH1 promoter hypermethylation | No additional testing | No | Community |
C | Bethesda Criteria | Bethesda Criteria | Suggestive histologic features | IHC for MSH6 and PMS2 | No additional tests | Not applicable; BRAF not performed | Non-reference private laboratory | |
D | Clinician request | Clinician request | Clinician request | Both DNA-PCR and IHC | Clinician request | Clinician request | Private reference laboratory | |
E | Other | Other | Other | Other | BRAF mutation and MLH1 promoter hypermethylation | |||
